Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-World Outcomes Following First-Line Treatment in Patients with Advanced Ovarian Cancer with Multiple Risk Factors for Disease Progression who Received Maintenance Therapy or Active Surveillance.
Chase D, Perhanidis J, Gupta D, Kalilani L, Golembesky A, González-Martín A. Chase D, et al. Among authors: kalilani l. Oncol Ther. 2023 Jun;11(2):245-261. doi: 10.1007/s40487-023-00227-6. Epub 2023 Apr 4. Oncol Ther. 2023. PMID: 37016186 Free PMC article.
Cytochrome P450 inhibitor/inducer treatment patterns among patients in the United States with advanced ovarian cancer who were prescribed or were eligible for poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors in the first-line maintenance setting.
Rimel BJ, Chase DM, Perhanidis J, Ghazarian AA, Du EX, Wang T, Song J, Golembesky AK, Hurteau JA, Kalilani L, Salani R, Monk BJ. Rimel BJ, et al. Among authors: kalilani l. Gynecol Oncol Rep. 2024 Feb 7;51:101332. doi: 10.1016/j.gore.2024.101332. eCollection 2024 Feb. Gynecol Oncol Rep. 2024. PMID: 38362364 Free PMC article.
Characteristics and real-world outcomes of patients with epithelial ovarian cancer who received niraparib plus bevacizumab first-line maintenance therapy in the COMB1NE study.
Thaker PH, Areli Calderón Boyle T, Burns S, Lim J, Hartman J, Kalilani LV, Schilder JM, Hurteau JA, Golembesky AK. Thaker PH, et al. Among authors: kalilani lv. Int J Gynecol Cancer. 2024 Dec 2;34(12):1924-1931. doi: 10.1136/ijgc-2024-005611. Int J Gynecol Cancer. 2024. PMID: 39244209 Free PMC article.
The Utility of ctDNA in Lung Cancer Clinical Research and Practice: A Systematic Review and Meta-Analysis of Clinical Studies.
Sun X, Abrahamson P, Ballew N, Kalilani L, Phiri K, Bell KF, Slowley A, Zajac M, Hofstatter E, Stojadinovic A, Silvestro A, Wang Z, Aziez A, Peters S. Sun X, et al. Among authors: kalilani l. Cancer Invest. 2023 Jul;41(6):571-592. doi: 10.1080/07357907.2023.2220820. Epub 2023 Jun 18. Cancer Invest. 2023. PMID: 37272675 Free article. Review.
63 results